AGAP2 and AIDS dementia complex: In addition, the TBILA/AGAP2-AS1/Cyfra21-1 combination yielded optimal diagnostic efficiency for ADC patients (AUC: 0.815, Table 5, Fig. 6C) and SCC patients (AUC: 0.895, Table 5, Fig. 6D).